International

fitness

Farmmi Participates in Shanghai International Health, Wellness and Fitness Expo

LISHUI, China, Nov. 30, 2020 /PRNewswire/ — Farmmi, Inc. (“Farmmi” or the “Company”) (NASDAQ: FAMI), an agriculture products supplier in China, today announced its participation in the Shanghai International Health, Wellness and Fitness Expo (the “Expo”), which was held from November 25 to 27, 2020. The Expo, the largest of its kind in Asia, included edible fungi in its featured products.

The Expo covered a total exhibition area of 54,000 square meters, with 452 national and international brands, gathering 43,076 domestic and international buyers.

Ms. Yefang Zhang, Farmmi’s Chairwoman and CEO, commented, “While we have done an excellent job closing sales opportunities in the new virtual world of 2020, it was exciting for us to get back in front of customers and partners at the Expo. The organizers put necessary safety controls in place to ensure the health of attendees. We thank them for their efforts in making this such a successful expo for all participants.”

“With the improvement of living standards, people are becoming more particular about their health and diet. Farmmi is benefitting from inclusion and wider adoption of edible fungi, which are now a standard part of the new healthy diet structure. Low calorie bacteria with high protein, low fat and high efficacy are now recognized worldwide as nutritional, health foods,” continued Ms. Zhang. “As a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products, Farmmi has the scale and strict controls to build upon customer demand growth worldwide.”

Ms. Zhang concluded, “The Expo, which emphasized technology and innovation, served as an important platform for our company to meet customers, promote products, carry out industry exchanges and seek cooperation opportunities. This is fully in-line with our strategy to seek out and execute on increased business opportunities in both the domestic China market and worldwide.”

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms, other edible fungi, and many other sought-after agricultural products. The Company’s Farmmi Liangpin Market serves as a trading platform for Chinese geographical indication agricultural products and is a large platform for consumers to access locally sourced agricultural products. For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including the potential impact of COVID-19 on our business within and outside of China. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”

Read More
fitness

Tottenham star Steven Bergwijn sent home from international duty with Holland due to fitness issues

Tottenham star Steven Bergwijn sent home from international duty with Holland due to ‘fitness issues’ – despite playing for Spurs last week in Europa League victory away at Ludogorets

  • Steven Bergwijn was called up to the Dutch national team by Frank de Boer
  • He has now already been sent home by Holland coaches due to ‘fitness issues’
  • The midfielder played for Tottenham away at Ludogorets on Thursday night
  • Holland have games against Spain, Bosnia and Poland in the coming days 

Steven Bergwijn has returned to Tottenham without playing a minute of football for Holland in the international break after coaches deemed him not fit enough for action – despite him playing for Spurs last week.

The midfielder has dropped down the pecking order slightly under Mourinho, seeing his game-time limited in recent weeks, but he has played in both of Spurs’ most recent Europa League games, starting in Antwerp and coming on at Ludogorets.

He was called up by the Dutch national team for their upcoming fixtures, but is now already back in London after being sent home for fitness issues.

Steven Bergwijn has been sent home from Holland duty this week due to fitness issues

Steven Bergwijn has been sent home from Holland duty this week due to fitness issues

The Tottenham midfielder played as recently as last Thursday in the Europa League

The Tottenham midfielder played as recently as last Thursday in the Europa League

In a statement from the Dutch FA, it was confirmed: ‘Steven Bergwijn has left the training camp of the Dutch national team. The Tottenham Hotspur attacker was examined by the medical staff of Oranje on Monday, upon arrival in Zeist. 

‘It turned out that he is not fit enough and that the Oranje matches must pass by.

‘National coach Frank de Boer is not calling for a replacement, so the selection of the Dutch national team now consists of 24 players.’

Bergwijn started against Royal Antwerp the week before, but isn't fit enough for Holland

Bergwijn started against Royal Antwerp the week before, but isn’t fit enough for Holland

Bergwijn (centre) trains with Spurs last week - he has dropped down the pecking order slightly

Bergwijn (centre) trains with Spurs last week – he has dropped down the pecking order slightly

Holland play Spain on Wednesday night, before Nations League matches against Bosnia & Herzegovina and Poland.

They will now have to contend those three matches without one of their more impressive midfield stars, with Bergwijn having to watch on TV instead.

The 23-year-old did suffer a hamstring injury just before the coronavirus shutdown last season, and there are concerns that he still hasn’t quite shaken that off.

Advertisement

Source Article

Read More
medicine

Worldwide Regenerative Medicine Industry to 2025 – Featuring Allergan, Amgen and Baxter International Among Others

DUBLIN, Nov. 9, 2020 /PRNewswire/ — The “Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025” report has been added to ResearchAndMarkets.com’s offering.

The global regenerative medicine market grew at a CAGR of around 16% during 2014-2019. Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. It involves the utilization of stem cells that are developed in laboratories and further implanted safely into the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies. They hold potential for the effective treatment of various chronic diseases, such as Alzheimer’s, Parkinson’s and cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries.

The increasing prevalence of chronic medical ailments and genetic disorders across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is prone to various musculoskeletal, phonological, dermatological and cardiological disorders, is stimulating the market growth. In line with this, widespread adoption of organ transplantation is also contributing to the market growth. Regenerative medicine minimizes the risk of organ rejection by the body post-transplant and enhances the recovery speed of the patient.

Additionally, various technological advancements in cell-based therapies, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative medicines, are acting as other growth-inducing factors. These advancements also aid in conducting efficient dermatological grafting procedures to treat chronic burns, bone defects and wounds on the skin. Other factors, including extensive research and development (R&D) activities in the field of medical sciences, along with improving healthcare infrastructure, are anticipated to drive the market further. Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan PLC (AbbVie Inc.), Amgen Inc., Baxter International Inc., BD (Becton, Dickinson and Company), Integra Lifesciences Holdings Corporation, Medtronic plc, Mimedx Group Inc., Novartis AG, Osiris Therapeutics Inc. (Smith & Nephew plc) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

  • How has the global regenerative medicine market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global regenerative medicine market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global regenerative medicine market and who are the key players?
  • What is the degree of
Read More
health

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial

Amgen and Eisai to Participate in the Immune Modulation Domain of REMAP-COVID, an Adaptive Clinical Trial to Test Interventions for Patients Hospitalized With COVID-19

Amgen’s Apremilast and Eisai’s Eritoran to Be Evaluated Across Multiple International Trial Sites Within the REMAP Network

Global Coalition for Adaptive Research (LOS ANGELES, CA), Amgen (THOUSAND OAKS, CA), and Eisai Co., Ltd. (TOKYO, Japan “Eisai”) — The Global Coalition for Adaptive Research (GCAR) in collaboration with Amgen and Eisai Co., Ltd., today announced enrollment of the first patient in the immune modulation domain of REMAP-COVID, a sub-study of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. Amgen’s apremilast and Eisai’s investigational eritoran are being evaluated as potential therapeutic agents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005657/en/

REMAP-CAP was developed to test treatments for severe pneumonia both in non-pandemic and pandemic settings. In February 2020, REMAP-CAP rapidly pivoted to its pandemic mode (the REMAP-COVID sub-study), as per its original intent, to incorporate additional potential treatment regimens specifically targeting COVID-19 and to expand enrollment to COVID-19 patients. This trial is a multicenter, randomized platform study, with treatments tested within groupings or “domains” based on pathway or mechanism of action.

The trial is being conducted in the multi-hospital UPMC (University of Pittsburgh Medical Center) health system along with over 20 hospitals in the United States. Additional global sites across the trial network will follow. University of Pittsburgh is serving as the U.S. Regional Coordinating Center.

“Partnering with the biopharmaceutical industry to be able to efficiently test well-understood targeted agents is critical to understanding treatment paradigms for COVID-19 patients,” says Derek Angus, MD, MPH, FRCP, U.S. Principal Investigator of REMAP and Chief Healthcare Innovation Officer, UPMC Health System. “Today’s announcement marks an important milestone in the collaboration between industry and the scientific and academic community to work collectively to evaluate potentially promising therapies to support patients hospitalized with COVID-19.”

Amgen’s apremilast is an oral drug which inhibits the activity of PDE4 (Phosphodiesterase 4), an enzyme found in inflammatory cells in the human body. By inhibiting PDE4, apremilast is thought to modulate the production of inflammatory cytokines and other mediators, which may prove helpful in inhibiting the inflammatory response associated with the signs, symptoms and pulmonary involvements observed in some COVID-19 patients. Apremilast is currently approved for use in more than 45 countries as an oral treatment for inflammatory diseases including moderate to severe plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behcet’s disease.

“Amgen believes that, based on its mechanism of action, apremilast might help prevent the respiratory distress seen in moderate to severe-stage adult COVID-19 patients,” said David M. Reese, M.D., Executive Vice President of Research and Development at Amgen. “We are proud to be joining REMAP-COVID, which is an important and innovative effort utilizing a platform approach and has the potential to rapidly identify whether apremilast

Read More
health

On International Pronouns Day, transgender women talk inner strength, outer beauty

Wednesday marked the third annual International Pronouns Day, which is meant to educate and raise awareness about the importance of respecting personal pronouns.

This day, and the push to make asking and using other people’s personal pronouns commonplace, spotlights an issue that particularly affects the transgender and gender nonconforming communities, experts have said.

Two transgender women and a Northwell Health surgeon spoke at a livestreamed event organized by the hospital on Wednesday about some of the issues facing the transgender community.

Rubi Lacroix, 25, of Babylon, who grew up in Gramercy Park, and Demi Washington, 28, a South Carolina native who now lives in Brooklyn, underwent facial feminization surgery and spoke about their experiences alongside Dr. James Bradley.

The operations last seven hours or so as chins and jaws are softened, noses and brows re-sculpted and hairlines lowered, experts said.

“I have a softer face now,” Washington said. “It is easier for people to see me as a woman.”

Said Lacroix, on her way to becoming an X-ray technician and then a nurse: “It was really tough; I had to do this.”

About one half of transgender boys attempted suicide in their teens; for girls the rate was nearly one-third and for nonbinary individuals, whose identities fall outside of the gender binary, the figure was just under 42%, an October 2018 American Academy of Pediatrics study found.

“This is not about hair and makeup … this is a life-changing procedure not easily recovered from,” Washington said.

During the recovery, said Washington, “There is a lot of time to think about what it means to have the exterior features of a woman. This doesn’t erase anybody’s strife — now, all of a sudden you’re thoroughly deemed a sexual being. Now I’m reduced to the exterior, the woman you happen to see.”

“You have to be very strong to (handle) the transitions,” Washington added.

Crimes against transgender individuals appear to be on the rise by some measures, though they likely are quite undercounted because people are wary of how they will be treated — and some are not out.

Two years ago, 10 hate crimes against transgender individuals or their property were reported in New York State, down from 14 in 2017, Division of Criminal Justice Services statistics show. There were 18 such hate crimes in 2016, and one in 2014 and 2015.

For nonbinary individuals, who may prefer to be addressed with plural pronouns instead of as “he” or “she,” there were four hate crimes reported in 2018, zero in 2017, and five in 2016. Two were tracked in 2015, three in 2014.

Like many transgender individuals, Lacroix knew early on that her body did not match who she was on the inside.

“I think this is the best decision I ever made in my life,” she said. “Now, people

Read More